Tenofovir
- Generic Name
- Tenofovir
- Brand Names
- Vemlidy, Tenofovir disoproxil Zentiva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H14N5O4P
- CAS Number
- 147127-20-6
- Unique Ingredient Identifier
- W4HFE001U5
- Background
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in ...
- Indication
Tenofovir has been shown to be effective against HIV, herpes simplex virus-2, and hepatitis B virus.
To know more about the specific product indications, please visit the information in the orally available forms of tenofovir, tenofovir alafenamide and tenofovir disoproxil.
- Associated Conditions
- -
- Associated Therapies
- -
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 184
- Registration Number
- NCT02945163
- Locations
- 🇨🇳
Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
🇨🇳Yunnan provincial infectious disease hosipital, Kunming, Yunnan, China
🇨🇳The Second Hospital of Nanjing, Nanjing, Jiangsu, China
Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent
- Conditions
- Interventions
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT02888106
- Locations
- 🇷🇺
LLC "Clinic of Modern Medicine", Moscow, Russian Federation
🇷🇺Medical Company "Gepatolog" LLC, Samara, Russian Federation
🇷🇺State Budgetary Institution of healthcare 'Stavropol regional clinical hospital', Stavropol', Russian Federation
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
- Conditions
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02797522
- Locations
- 🇳🇿
Auckland Clinical Studies Ltd, Grafton, Auckland, New Zealand
A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
- Conditions
- Interventions
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- F-star Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02751996
- Locations
- 🇨🇳
Spring Bank Pharma Research Site, Taoyuan County, Taiwan
🇰🇷Spring Bank Pharma Research site, Seoul, Korea, Republic of
🇰🇷Spring Pharma Research Site, Chuncheon-si, Gangwon-do, Korea, Republic of
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2016-04-14
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02738008
- Locations
- 🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of
🇨🇳Queen Mary Hospital, Hong Kong, China
🇩🇪Eugastro Gmbh, Leipzig, Germany
Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 64
- Registration Number
- NCT02689245
- Locations
- 🇮🇳
Institute of liver and Biliary Sciences, New Delhi, Delhi, India
Adjuvant Entecavir or Tenofovir for Postoperative HBV-HCC
- First Posted Date
- 2016-01-08
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 240
- Registration Number
- NCT02650271
- Locations
- 🇨🇳
Department of Hepatobilliary Surgery, Affiliated Tumor of Guangxi University, Nanning, Guangxi, China
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02604212
- Locations
- 🇩🇪
Universitaetsklinikum Leipzig, Leipzig, Germany
🇩🇪Universitaetsklinikum Wuerzburg, Medizinische Klinik Und Poliklinik II, Wuerzburg, Germany
🇩🇪Medizinische Hochschule Hannover, Hannover, Germany
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Arrowhead Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT02604199
- Locations
- 🇰🇷
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
🇩🇪Eugastro Gmbh, Leipzig, Germany
🇩🇪University Hospital of Tuebingen, Tuebingen, Germany
To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT02585947
- Locations
- 🇰🇷
Seoul National University, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.